RxDoctor Payments Data

Dora Richardson

Nurse Practitioner · Seville, OHNPI 1922037332

Payments from drug & device makers

$2,602in general payments, 2019–2025

Across 111 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$686
  • Lilly USA, LLC$611
  • Teva Pharmaceuticals USA, Inc.$214
  • Novo Nordisk$149
  • Organogenesis Inc.$136
  • Lundbeck LLC$125
  • plus $681 from 16 others

What the payments were for

  • Food & beverage$2,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,602 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$37,627
Medicare patients
133
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$35,996
JardianceEmpagliflozin22$20,775
MounjaroTirzepatide19$20,538
FarxigaDapagliflozin Propanediol21$20,218
XareltoRivaroxaban28$19,643
OzempicSemaglutide15$17,184
Synjardy XrEmpagliflozin/Metformin Hcl12$7,116
Albuterol Sulfate HfaAlbuterol Sulfate88$2,409
Levothyroxine Sodium182$1,589
Gabapentin39$1,036
Cyclobenzaprine Hcl50$1,020
Gemfibrozil11$939
Duloxetine Hcl43$818
Atorvastatin Calcium117$783
Hydroxychloroquine Sulfate20$755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$35,99633 claims
Boehringer IngelheimJardiance, Synjardy Xr$30$27,89134 claims
Lilly USA, LLCMounjaro$611$20,53819 claims
AstraZenecaFarxiga$686$20,21821 claims
Novo NordiskOzempic$149$17,18415 claims
AbbVieSynthroid$119$46429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Seville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →